Showing 1 - 20 results of 30,601 for search '(( 17 sites decrease ) OR ((( _ largest decrease ) OR ( a ((we decrease) OR (a decrease)) ))))', query time: 0.55s Refine Results
  1. 1
  2. 2

    Table 1_Effect of decreased suspended sediment content on chlorophyll-a in Dongting Lake, China.docx by Le Zhang (88249)

    Published 2025
    “…However, the effect of reduced SSC on Chl-a is poorly studied. Here, we compared and analyzed the distribution conditions of Chl-a in 6 representative years for both before the implementation of Three Gorges Dam (TGD) (BIT) and after the implementation of TGD (AIT), using the TM/OLI data and NIR-red inversion model. …”
  3. 3

    Predicting pattern diversity decreases as a function of and . by Selim Haj Ali (21222613)

    Published 2025
    “…(a) and (b): Average negative predictive value for and , respectively for and . …”
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18

    The injectable contraceptives depot medroxyprogesterone acetate and norethisterone enanthate substantially and differentially decrease testosterone and sex hormone binding globulin levels: A secondary study from the WHICH randomized clinical trial by Chanel Avenant (409756)

    Published 2025
    “…<p dir="ltr">HIV acquisition risk with norethisterone (NET) enanthate (NET-EN) is reportedly less than for depo-medroxyprogesterone acetate intramuscular (DMPA-IM). We investigated the effects of these progestin-only injectable contraceptives on serum testosterone and sex hormone binding globulin (SHBG) levels, since these may play a role in sexual behavior and HIV acquisition. …”
  19. 19
  20. 20

    Table 1_Targeting nail psoriasis: IL-17A inhibitors demonstrate site-specific superiority over IL-23 inhibitor in a 24-week dermoscopy-guided real-world cohort.docx by Xiamei Yan (21014921)

    Published 2025
    “…Objective<p>To compare the real-world clinical efficacy and safety of interleukin (IL)-17A inhibitors (secukinumab [SEC] and ixekizumab [IXE]) versus the IL-23 inhibitor guselkumab (GUS) in patients with nail psoriasis, with a focus on site-specific biologic therapeutic responses (nail matrix vs. nail bed) in a 24-week prospective observational cohort.…”